---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009880"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:53:35.218798+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics provides pipeline update: CTX310 advances to Phase 1b; zugo-cel shows durable remission in SLE

## Summary
- CTX310 (ANGPTL3) advanced to Phase 1b for severe hypertriglyceridemia and refractory hypercholesterolemia after positive Phase 1 data.
- CTX320 (LPA) showed up to 73% reduction in dose escalation; next-gen CTX321 with ~2-fold greater potency in preclinical testing.
- Zugo-cel (CTX112): first SLE patient in drug-free DORIS remission at month 9; second SLE patient with SLEDAI-2K 0 at month 2.
- Collaboration with Eli Lilly to evaluate zugo-cel + pirtobrutinib in aggressive B-cell lymphomas.
- Next-gen diabetes candidate CTX213 progressing towards clinic after promising CTX211 data showing C-peptide at 12 months.

## SEC filing metadata
- accession: 0001193125-26-009880
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000119312526009880/0001193125-26-009880-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000119312526009880/crsp-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009880
- JSON: https://secwatch.observer/filing/0001193125-26-009880.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009880.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.